News

EMUC18 Karim Fizazi

Video: Update on PROSPER & SPARTAN Trials

In his lecture “Early hormonal manipulation in M0 CRPC”, Prof. Dr. Karim Fizazi (FR) stated that M0 CRPC is a rare situation and will become even rarer If next-generation imaging is used.

Identifying the frail kidney cancer patient

The first day of EMUC18 came to a close with a session on kidney cancer, specifically on the frailty of renal cancer patients. Dr. Umberto Capitanio (Milan, IT) gave a talk on the definitions of frailty, and the ways...
Albiges at EMUC

Deliberations on IO as first-line therapy for kidney cancer patients

In the point-counterpoint discussion “Immunotherapy for all patients as first line in kidney cancer?” in Plenary Session 04 “Immunotherapy: Evolving paradigms in GU cancers”, Dr. Laurence Albiges (FR) presented her insights in favour of immunotherapy (IO) as first-line treatment....

The future of good evidence gathering for PCa

New approaches to clinical trials can lead to more successful results in the challenging near future. Parallel, comparative studies and a better selection of patients are just some positive developments in the generation of useful evidence for prostate cancer...
EMUC_chairs

PCa management essentials opens EMUC’s 10th year

Throughout a decade, the European Multidisciplinary Congress on Urological Cancers (EMUC) has established its reputation as the leading platform where multidisciplinary specialists with expertise in urological malignancies come together. This year, EMUC commences in Amsterdam, The Netherlands. The programme...

Birtle to present key POUT findings and updates at EMUC18

The PeriOperative chemotheraphy or sUrveillance in upper Tract urothelial cancer, also known as POUT (CRUK/11/027; NCT01993979, NIHR portfolio) is the largest clinical trial in upper tract urothelial cancer (UTUC) with findings supporting the use of adjuvant platinum based chemotherapy...